Moreover, an attempt to predict outcomes with biological features showed that patients harboring TP53 mutations did not benefit from Venetoclax-HMA, whereas IDH-mutated AML showed higher response rates [58,60]. This evidence concerns the gene IDH2 and acute myeloid leukemia.